Iatrogenic Hyperkalemia Management

Definition and Classification

Iatrogenic hyperkalemia is elevated serum potassium (>5.0 mmol/L) caused by medications, medical interventions, or healthcare-related factors, often occurring in patients with cardiovascular disease, chronic kidney disease, diabetes, or advanced age 1, 2
Hyperkalemia is defined as serum potassium >5.0 mmol/L, with severity classified as mild (>5.0 to <5.5 mEq/L), moderate (5.5 to 6.0 mEq/L), or severe (>6.0 mEq/L) 3, 4
Iatrogenic hyperkalemia specifically refers to elevated potassium levels resulting from medical interventions, particularly medications 1, 2
The prevalence of iatrogenic hyperkalemia is approximately 2-4% in the general population but increases to 10-55% in hospitalized patients and up to 73% in those with advanced chronic kidney disease 2

Renin-angiotensin-aldosterone system inhibitors (RAASi): ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists 1
Potassium-sparing diuretics (spironolactone, triamterene, amiloride) 1
Beta-blockers (reduce renin release) 1
Non-steroidal anti-inflammatory drugs (NSAIDs) 1
Calcineurin inhibitors (cyclosporine, tacrolimus) 1
Trimethoprim-sulfamethoxazole 1
Heparin (suppresses aldosterone production) 1
Digitalis 1
Salt substitutes containing potassium 1
Stored blood products 1
Certain herbal supplements (alfalfa, dandelion, horsetail) 1
Mannitol 1

Often asymptomatic, especially in chronic cases 2
May present with muscle weakness, paresthesias, or cardiac arrhythmias 4
ECG changes: peaked T waves, flattened P waves, prolonged PR interval, widened QRS complex 4
Can lead to cardiac arrest and death if untreated 2

Confirm hyperkalemia with laboratory testing and rule out pseudohyperkalemia 2, 6
Pseudohyperkalemia can result from hemolysis during sample collection, excessive fist clenching, or delayed specimen processing 6
Obtain ECG to assess for cardiac effects 4
Review medication list for potential causative agents 4

Calcium chloride or calcium gluconate for cardiac membrane stabilization 4
Insulin with glucose or nebulized beta-2 agonists to shift potassium into cells 7, 4
Sodium bicarbonate if metabolic acidosis is present 7
Loop diuretics to increase renal potassium excretion 7
Potassium binders (sodium polystyrene sulfonate, patiromer, sodium zirconium cyclosilicate) 7
Hemodialysis for severe cases or when other measures fail 7
Identify and adjust causative medications 4
Consider dose reduction rather than discontinuation of beneficial medications (especially RAASi) 4
Dietary potassium restriction (<3 g/day) 4
Regular monitoring of serum potassium levels 4, 5
Consider newer potassium binders for long-term management 4

Regular monitoring of potassium levels in high-risk patients 5
More frequent monitoring after starting or adjusting doses of potassium-influencing medications 4
Failing to rule out pseudohyperkalemia before initiating treatment 6
Permanently discontinuing beneficial RAASi medications instead of adjusting doses 4
Delaying treatment of severe hyperkalemia while waiting for confirmation of repeat laboratory values 4
Overlooking ECG changes in patients with hyperkalemia 4, 6
Inadequate monitoring of high-risk patients on potassium-influencing medications 5